• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

    2/14/24 3:33:22 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email
    SC 13G/A 1 d10980632_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    LifeMD, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.01 per share
    (Title of Class of Securities)

     

     

    53216B104
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Act or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 53216B104    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Capital Management, LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,737,685  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,737,685  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,737,6851  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.8%1  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, PN

     

     

     

     

    1 As of December 31, 2023, each Reporting Person beneficially owned 1,846,632 shares of the Common Stock, par value $0.01 per share of the Issuer, constituting 4.9% of the Common Stock, par value $0.01 per share outstanding as of such date.

     
     

     

    CUSIP No. 53216B104    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      William Zolezzi  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,737,685  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,737,685  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,737,6852  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.8%2  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

    2 As of December 31, 2023, each Reporting Person beneficially owned 1,846,632 shares of the Common Stock, par value $0.01 per share of the Issuer, constituting 4.9% of the Common Stock, par value $0.01 per share outstanding as of such date.

     
     

     

     

    CUSIP No. 53216B104    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,737,685  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,737,685  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,737,6853  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.8%3  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     


    3 As of December 31, 2023, each Reporting Person beneficially owned 1,846,632 shares of the Common Stock, par value $0.01 per share of the Issuer, constituting 4.9% of the Common Stock, par value $0.01 per share outstanding as of such date.

     
     

     

     

    CUSIP No. 53216B104    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Partners GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,737,685  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,737,685  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,737,6854  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
             [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.8%4  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    HC, OO

     

     


    4 As of December 31, 2023, each Reporting Person beneficially owned 1,846,632 shares of the Common Stock, par value $0.01 per share of the Issuer, constituting 4.9% of the Common Stock, par value $0.01 per share outstanding as of such date.

     
     

     

     

    CUSIP No. 53216B104    

     

    Item 1. (a). Name of Issuer:  
           
        LifeMD, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    236 Fifth Avenue, Suite 400

    New York, New York 10001

     

     

    Item 2. (a). Name of person filing:  
           
       

    Divisadero Street Capital Management, LP

    Divisadero Street Partners, L.P.

    Divisadero Street Partners GP, LLC

    William Zolezzi

     

    Divisadero Street Capital Management, LP is the investment adviser to private investment funds, including Divisadero Street Partners, L.P., and Divisadero Street Partners GP, LLC is the general partner of Divisadero Street Partners, L.P. William Zolezzi is the control person of Divisadero Street Capital Management, LP and Divisadero Street Partners GP, LLC. Divisadero Street Capital Management, LP, Divisadero Street Partners, L.P., Divisadero Street Partners GP, LLC, and William Zolezzi (collectively, the “Filers”) are filing this statement jointly, but not as members of a group. Each Filer expressly disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Common Stock, par value $0.01 per share of LifeMD, Inc. except to the extent of that Filer’s pecuniary interest therein. The filing of this Schedule 13G on behalf of Divisadero Street Partners, L.P. should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Common Stock, par value $0.01 per share of LifeMD, Inc. covered by this Schedule 13G.

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Divisadero Street Capital Management, LP

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    Divisadero Street Partners, L.P.

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    Divisadero Street Partners GP, LLC

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    William Zolezzi

    c/o Divisadero Street Capital Management, LP

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

     

      (c). Citizenship:  
       

     

    Divisadero Street Capital Management, LP – Delaware

    Divisadero Street Partners, L.P. – Delaware

    Divisadero Street Partners GP, LLC – Delaware

    William Zolezzi – United States of America

     

     

      (d).   Title of class of securities:  
           
        Common Stock, par value $0.01 per share  

     

      (e). CUSIP No.:  
           
        53216B104  
     
     

     

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [x] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [x] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    Divisadero Street Capital Management, LP – 3,737,685

    Divisadero Street Partners, L.P. – 3,737,685

    Divisadero Street Partners GP, LLC – 3,737,685

    William Zolezzi – 3,737,685

     

      (b)   Percent of class:
         
       

    Divisadero Street Capital Management, LP – 9.8%

    Divisadero Street Partners, L.P. – 9.8%

    Divisadero Street Partners GP, LLC – 9.8%

    William Zolezzi – 9.8%

     

      (c)   Number of shares as to which the person has:
         

     

        (i) Sole power to vote or to direct the vote    

     

         

    Divisadero Street Capital Management, LP – 0

    Divisadero Street Partners, L.P. – 0

    Divisadero Street Partners GP, LLC – 0

    William Zolezzi – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Divisadero Street Capital Management, LP – 3,737,685

    Divisadero Street Partners, L.P. – 3,737,685

    Divisadero Street Partners GP, LLC – 3,737,685

    William Zolezzi – 3,737,685

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Divisadero Street Capital Management, LP – 0

    Divisadero Street Partners, L.P. – 0

    Divisadero Street Partners GP, LLC – 0

    William Zolezzi – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Divisadero Street Capital Management, LP – 3,737,685

    Divisadero Street Partners, L.P. – 3,737,685

    Divisadero Street Partners GP, LLC – 3,737,685

    William Zolezzi – 3,737,685

     

     

     
     

     

     

      Instruction:  For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
       
    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      All securities reported in this Schedule 13G are owned by advisory clients of Divisadero Street Capital Management, LP.  None of the advisory clients individually own more than 5% of the outstanding Common Stock, par value $0.01 per share of LifeMD, Inc.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2024
      (Date)
     

     

    DIVISADERO STREET CAPITAL MANAGEMENT, LP*

       
      By: Divisadero Street Capital LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

     

      DIVISADERO STREET PARTNERS, L.P*
       
      By: Divisadero Street Partners GP, LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

     

      DIVISADERO STREET PARTNERS GP, LLC*
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

    WILLIAM ZOLEZZI*

     

    /s/ William Zolezzi

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Divisadero Street Capital Management, LP, as the undersigned’s true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

      February 14, 2024
      (Date)
     

     

    DIVISADERO STREET CAPITAL MANAGEMENT, LP

       
      By: Divisadero Street Capital LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

     

      DIVISADERO STREET PARTNERS, L.P
       
      By: Divisadero Street Partners GP, LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

     

      DIVISADERO STREET PARTNERS GP, LLC
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

     

     

      WILLIAM ZOLEZZI
       
      /s/ William Zolezzi
       

     

     

    Get the next $LFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    3/10/2022$14.00Buy
    Colliers Securities
    More analyst ratings

    $LFMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by LifeMD Inc.

      10-Q - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:45:42 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:10:25 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LifeMD, Inc. (0000948320) (Filer)

      4/28/25 8:47:43 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

      NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's a

      5/22/25 8:05:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD to Participate in Three Investor Conferences During May

      NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.B. Riley Securities 25th Annual Institutional Investor Conference, May 21-22 at the Ritz-Carlton in Marina Del Rey. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.Craig-Hallum 22nd Annual Institutional Investor Conference, May 28 at The Depo

      5/12/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform. LifeMD's weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single,

      4/29/25 8:05:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on LifeMD with a new price target

      Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

      12/10/24 8:29:49 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Mizuho initiated coverage on LifeMD with a new price target

      Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

      12/4/24 7:42:36 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • B. Riley Securities resumed coverage on LifeMD with a new price target

      B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00

      8/23/24 8:12:47 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      9/12/24 2:10:03 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chairman and CEO Schreiber Justin sold $188,223 worth of shares (25,000 units at $7.53) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      5/5/25 6:02:56 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chairman and CEO Schreiber Justin sold $389,040 worth of shares (50,000 units at $7.78) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      5/1/25 4:47:52 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Stan Maria E. was granted 139,375 shares, increasing direct ownership by 205% to 207,500 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      4/3/25 2:52:40 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Set to Join the Russell 3000 Index

      NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

      5/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints Dr. Calum MacRae to its Board of Directors

      NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

      4/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints William J. Febbo to its Board of Directors

      NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec

      6/20/23 8:00:00 AM ET
      $LFMD
      $OPRX
      Medical/Nursing Services
      Health Care
      Business Services
      Consumer Discretionary

    $LFMD
    Financials

    Live finance-specific insights

    See more
    • Medifast Announces First Quarter 2025 Financial Results

      Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we

      4/28/25 4:05:00 PM ET
      $LFMD
      $MED
      Medical/Nursing Services
      Health Care
      Packaged Foods
      Consumer Staples
    • LifeMD to Report First Quarter 2025 Financial Results on May 6

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a

      4/28/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Acquires Women's Health Provider Optimal Human Health MD to Accelerate Entry into the Women's Health Market

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses

      4/28/25 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      11/14/24 10:42:44 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      2/14/24 3:33:22 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by LifeMD Inc.

      SC 13G - LifeMD, Inc. (0000948320) (Subject)

      10/6/23 5:26:16 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care